LINC00632 and melanoma: Interestingly, when we reviewed a study (GSE60666) [36] on the treatment of melanoma cell lines by (+)-JQ1 (thieno-triazolo-1,4-diazepine, a well-reported BRD4 (bromodomain-containing protein 4) inhibitor [59, 60]), we found that the cell line derived from male patients showed elimination of epigenetic silencing of LINC00632, while the data from female patients remained unchanged (Supplementary Figure S11A and B).